Literature DB >> 16684319

Double heterozygotes for non-Caucasian families with mutations in BRCA-1 and BRCA-2 genes.

Doo Ho Choi1, Min Hyuk Lee, Bruce G Haffty.   

Abstract

The recent discovery of the BRCA-1 and BRCA-2 genes as contributing factors to hereditary breast cancer has significantly improved our understanding of familial breast cancer. Deleterious mutations in both BRCA-1 and BRCA-2 in an individual patient is exceedingly rare, with few case reports in the literature, particularly among non-Caucasian, non-Jewish families. We describe here two cases of deleterious mutations in both genes in a cohort of Korean women with early onset breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684319     DOI: 10.1111/j.1075-122X.2006.00245.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  4 in total

1.  Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.

Authors:  O Lavie; S Narod; F Lejbkowicz; S Dishon; Y Goldberg; O Gemer; G Rennert
Journal:  Ann Oncol       Date:  2010-10-05       Impact factor: 32.976

2.  Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.

Authors:  Margaret Smith; Susan Fawcett; Emanouil Sigalas; Richard Bell; Sophie Devery; Nikolina Andrieska; Ingrid Winship
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375

3.  Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer.

Authors:  Lu Wen; Xiuxiu Li; Junping Shi; Shuo Zhang; Rui Wang; Ming Yao; Jun Guo
Journal:  J Int Med Res       Date:  2019-11-27       Impact factor: 1.671

4.  Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family.

Authors:  Raffaele Palmirotta; Domenica Lovero; Luigia Stefania Stucci; Erica Silvestris; Davide Quaresmini; Angela Cardascia; Franco Silvestris
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.